![Semaglutide (wegovy) is now FDA-approved as a weight loss medication: Scott D. Isaacs, MD: Endocrinologist Semaglutide (wegovy) is now FDA-approved as a weight loss medication: Scott D. Isaacs, MD: Endocrinologist](https://sa1s3optim.patientpop.com/assets/images/provider/photos/2363047.jpg)
Semaglutide (wegovy) is now FDA-approved as a weight loss medication: Scott D. Isaacs, MD: Endocrinologist
![Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care? - ScienceDirect Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care? - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1751991820302333-gr1.jpg)
Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care? - ScienceDirect
![Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care? - ScienceDirect Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care? - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1751991820302333-gr2.jpg)
Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care? - ScienceDirect
![More Evidence Once-Weekly Semaglutide Injection Helps People With Diabetes Lose Weight | Everyday Health More Evidence Once-Weekly Semaglutide Injection Helps People With Diabetes Lose Weight | Everyday Health](https://images.everydayhealth.com/images/more-evidence-semaglutide-helps-people-with-diabetes-lose-at-least-5-percent-of-body-weight-1440x810.jpg?sfvrsn=45c5e8ff_1)
More Evidence Once-Weekly Semaglutide Injection Helps People With Diabetes Lose Weight | Everyday Health
![Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial - The Lancet Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial - The Lancet](https://www.thelancet.com/cms/attachment/710d17bf-4ec1-407e-afd8-296d5ef58149/gr1.gif)